Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Research Article
[키워드] activated
Affect
allergy
Allostery
antibodies
approved
Asthma
B cell
B-cell
B-cells
bind
binding
Blood
bruton tyrosine kinase
BTK
BTK inhibitor
BTK inhibitors
Cancer
Cancer cells
cancers
catalytic activity
change
Chemotherapy
conformational
consequence
COVID-19
Diseases
disorder
disrupt
disrupting
domain
domains
drug
drug resistance
drugs
Effect
effective
enzyme
examined
FIVE
full-length
full-length protein
Future
help
hydrogen/deuterium exchange mass spectrometry
Ibrutinib
inactive
increase
inhibitor
inhibitors
Interaction
Joseph
Kinase inhibitor
leukemia
lymphoma
lymphomas
maintain
mechanism
modify
Mutation
None
not affect
nuclear magnetic resonance
other compound
other disease
phosphate
Previous effort
Protein
Proteins
Region
regions
Regulatory
regulatory domain
regulatory region
Research
responsible
shifting
treat
treated
treating COVID-19
Treatment
treatment strategy
tyrosine
understanding
while
White blood cell
[DOI] 10.7554/eLife.60470 PMC 바로가기 [Article Type] Research Article
[DOI] 10.7554/eLife.60470 PMC 바로가기 [Article Type] Research Article